- Previous Close
622.65 - Open
551.00 - Bid 578.45 x --
- Ask 581.90 x --
- Day's Range
551.00 - 583.20 - 52 Week Range
530.70 - 1,675.25 - Volume
49,124 - Avg. Volume
42,146 - Market Cap (intraday)
53.257B - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
15.48 - EPS (TTM)
37.30 - Earnings Date May 20, 2025 - May 24, 2025
- Forward Dividend & Yield 2.50 (0.40%)
- Ex-Dividend Date Sep 9, 2024
- 1y Target Est
1,373.00
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
www.strides.com3,065
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: STAR.BO
View MorePerformance Overview: STAR.BO
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STAR.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STAR.BO
View MoreValuation Measures
Market Cap
57.43B
Enterprise Value
77.16B
Trailing P/E
16.69
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.30
Price/Book (mrq)
2.53
Enterprise Value/Revenue
1.75
Enterprise Value/EBITDA
8.89
Financial Highlights
Profitability and Income Statement
Profit Margin
77.07%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
45.79B
Net Income Avi to Common (ttm)
3.42B
Diluted EPS (ttm)
37.30
Balance Sheet and Cash Flow
Total Cash (mrq)
2.47B
Total Debt/Equity (mrq)
104.22%
Levered Free Cash Flow (ttm)
--